{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:15:13Z","timestamp":1773404113473,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Transfer-Bonuns","award":["TB2799\/2020"],"award-info":[{"award-number":["TB2799\/2020"]}]},{"name":"Berlin Cures Holding AG","award":["no number available"],"award-info":[{"award-number":["no number available"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>COVID-19 is a pandemic respiratory disease that is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-SARS-CoV-2 antibodies are essential weapons that a patient with COVID-19 has to combat the disease. When now repurposing a drug, namely an aptamer that interacts with SARS-CoV-2 proteins for COVID-19 treatment (BC 007), which is, however, a neutralizer of pathogenic autoantibodies in its original indication, the possibility of also binding and neutralizing anti-SARS-CoV-2 antibodies must be considered. Here, the highly specific virus-neutralizing antibodies have to be distinguished from the ones that also show cross-reactivity to tissues. The last-mentioned could be the origin of the widely reported SARS-CoV-2-induced autoimmunity, which should also become a target of therapy. We, therefore, used enzyme-linked immunosorbent assay (ELISA) technology to assess the binding of well-characterized publicly accessible anti-SARS-CoV-2 antibodies (CV07-209 and CV07-270) with BC 007. Nuclear magnetic resonance spectroscopy, isothermal calorimetric titration, and circular dichroism spectroscopy were additionally used to test the binding of BC 007 to DNA-binding sequence segments of these antibodies. BC 007 did not bind to the highly specific neutralizing anti-SARS-CoV-2 antibody but did bind to the less specific one. This, however, was a lot less compared to an autoantibody of its original indication (14.2%, range 11.0\u201321.5%). It was also interesting to see that the less-specific anti-SARS-CoV-2 antibody also showed a high background signal in the ELISA (binding on NeutrAvidin-coated or activated but noncoated plastic plate). These initial experiments suggest that the risk of binding and neutralizing highly specific anti-SARS CoV-2 antibodies by BC 007 should be low.<\/jats:p>","DOI":"10.3390\/v13050932","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T06:01:33Z","timestamp":1621317693000},"page":"932","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Aptamer BC 007\u2019s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-1002","authenticated-orcid":false,"given":"Annekathrin","family":"Haberland","sequence":"first","affiliation":[{"name":"Berlin Cures GmbH, Robert-R\u00f6ssle-Str. 10 Blg. D79, 13125 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oxana","family":"Krylova","sequence":"additional","affiliation":[{"name":"Leibniz-Forschungsinstitut f\u00fcr Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP), Robert-R\u00f6ssle-Str. 10, 13125 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Nikolenko","sequence":"additional","affiliation":[{"name":"Leibniz-Forschungsinstitut f\u00fcr Molekulare Pharmakologie im Forschungsverbund Berlin e.V. (FMP), Robert-R\u00f6ssle-Str. 10, 13125 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3553-390X","authenticated-orcid":false,"given":"Peter","family":"G\u00f6ttel","sequence":"additional","affiliation":[{"name":"Berlin Cures GmbH, Knesebeckstr. 59-61, 10719 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0141-2635","authenticated-orcid":false,"given":"Andre","family":"Dallmann","sequence":"additional","affiliation":[{"name":"Department of Chemistry, NMR Facility, Humboldt University of Berlin, Brook-Taylor-Stra\u00dfe 2, 12489 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Berlin Cures GmbH, Knesebeckstr. 59-61, 10719 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardy","family":"Weisshoff","sequence":"additional","affiliation":[{"name":"Department of Chemistry, NMR Facility, Humboldt University of Berlin, Brook-Taylor-Stra\u00dfe 2, 12489 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Weisshoff, H., Krylova, O., Nikolenko, H., D\u00fcngen, H.-D., Dallmann, A., Becker, S., G\u00f6ttel, P., M\u00fcller, J., and Haberland, A. (2020). Aptamer BC 007\u2014Efficient Binder of Spreading-Crucial SARS-CoV-2 Proteins. Heliyon, 6.","DOI":"10.1016\/j.heliyon.2020.e05421"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40261-020-00903-9","article-title":"A Three-Part, Randomised Study to Investigate the Safety, Tolerability, Pharmacokinetics and Mode of Action of BC 007, Neutraliser of Pathogenic Autoantibodies Against G-Protein Coupled Receptors in Healthy, Young and Elderly Subjects","volume":"49","author":"Becker","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2016.06.061","article-title":"Aptamer BC 007\u2014A Broad Spectrum Neutralizer of Pathogenic Autoantibodies against G-Protein-Coupled Receptors","volume":"789","author":"Haberland","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_4","first-page":"65","article-title":"The DNA-Based Drug BC 007 Neutralizes Agonistically Acting Autoantibodies Directed Against G Protein\u2013Coupled Receptors Successful Mode of Action Demonstrated in Clinical Phase 1 Trial","volume":"37","author":"Haberland","year":"2019","journal-title":"Chem. Today"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e006155","DOI":"10.1161\/CIRCHEARTFAILURE.119.006155","article-title":"\u03921-Adrenoreceptor Autoantibodies in Heart Failure: Physiology and Therapeutic Implications","volume":"13","author":"Dordevic","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"102524","DOI":"10.1016\/j.autrev.2020.102524","article-title":"Could Sars-Coronavirus-2 Trigger Autoimmune and\/or Autoinflammatory Mechanisms in Genetically Predisposed Subjects?","volume":"19","author":"Caso","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102695","DOI":"10.1016\/j.autrev.2020.102695","article-title":"SARS-CoV-2, the Autoimmune Virus","volume":"19","author":"Halpert","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_8","first-page":"1","article-title":"A Rare Case of Acute Motor Axonal Neuropathy and Myelitis Related to SARS-CoV-2 Infection","volume":"17","author":"Masuccio","year":"2020","journal-title":"J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102506","DOI":"10.1016\/j.jaut.2020.102506","article-title":"Autoinflammatory and Autoimmune Conditions at the Crossroad of COVID-19","volume":"114","author":"Novelli","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, E.Y., Mao, T., Klein, J., Dai, Y., Huck, J.D., Liu, F., Zheng, N.S., Zhou, T., Israelow, B., and Wong, P. (2020). Diverse Functional Autoantibodies in Patients with COVID-19. medRxiv.","DOI":"10.1101\/2020.12.10.20247205"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102592","DOI":"10.1016\/j.jaut.2020.102592","article-title":"The JANUS of Chronic Inflammatory and Autoimmune Diseases Onset during COVID-19\u2014A Systematic Review of the Literature","volume":"117","author":"Novelli","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/d41586-021-00149-1","article-title":"Rogue Antibodies Could Be Driving Severe COVID-19","volume":"590","author":"Khamsi","year":"2021","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100073","DOI":"10.1016\/j.jtauto.2020.100073","article-title":"Prevalence of Autoantibody Responses in Acute Coronavirus Disease 2019 (COVID-19)","volume":"3","author":"Lerma","year":"2020","journal-title":"J. Transl. Autoimmun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100100","DOI":"10.1016\/j.jtauto.2021.100100","article-title":"Functional Autoantibodies against G-Protein Coupled Receptors in Patients with Persistent Long-COVID-19 Symptom","volume":"4","author":"Wallukat","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/355564a0","article-title":"Selection of Single-Stranded DNA Molecules That Bind and Inhibit Human Thrombin","volume":"355","author":"Bock","year":"1992","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A Neutralizing Human Antibody Binds to the N-Terminal Domain of the Spike Protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","article-title":"Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients","volume":"182","author":"Kreer","year":"2020","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients\u2019 B Cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent Neutralizing Antibodies from COVID-19 Patients Define Multiple Targets of Vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A Noncompeting Pair of Human Neutralizing Antibodies Block COVID-19 Virus Binding to Its Receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.cell.2020.09.049","article-title":"A Therapeutic Non-Self-Reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model","volume":"183","author":"Kreye","year":"2020","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in Humanized Mice and Convalescent Humans Yield a SARS-CoV-2 Antibody Cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jones, B.E., Brown-Augsburger, P.L., Corbett, K.S., Westendorf, K., Davies, J., Cujec, T.P., Wiethoff, C.M., Blackbourne, J.L., Heinz, B.A., and Foster, D. (2020). LY-CoV555, a Rapidly Isolated Potent Neutralizing Antibody, Provides Protection in a Non-Human Primate Model of SARS-CoV-2 Infection. bioRxiv.","DOI":"10.1101\/2020.09.30.318972"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently Neutralizing and Protective Human Antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Luscombe, N.M., and Thornton, J.M. (2002). Protein-DNA Interactions: Amino Acid Conservation and the Effects of Mutations on Binding Specificity. J. Mol. Biol., 320.","DOI":"10.1016\/S0022-2836(02)00571-5"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1093\/nar\/gkg563","article-title":"ExPASy: The Proteomics Server for in-Depth Protein Knowledge and Analysis","volume":"31","author":"Gasteiger","year":"2003","journal-title":"Nucleic Acids Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/932\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:03:05Z","timestamp":1760162585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["v13050932"],"URL":"https:\/\/doi.org\/10.3390\/v13050932","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]}}}